News

BlockBeats News, June 5th, JPMorgan Chase announced that it has raised its price target for a company from $160 to $265. According to Bitget market data, the pre-market trading price of the company dropped by 2.05% to $237.6.

Glonghui, June 5｜Biogen (BIIB.US) rose 3.8% pre-market to $204. According to reports, Biogen announced that the U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to salanersen for the treatment of spinal muscular atrophy (SMA). The breakthrough therapy designation aims to accelerate the development and review process of drugs for serious diseases, provided that preliminary clinical evidence indicates the drug may demonstrate substantial improvement over existing therapies on clinically significant endpoints. Salanersen is a novel antisense oligonucleotide (ASO) under development and is expected to deliver highly effective results in SMA treatment with an annual dosing regimen.

Abakkus Mutual Fund pointed out that against the complex backdrop of elevated crude oil prices, tense geopolitical situation in the Middle East, persistent exchange rate volatility, and renewed inflation concerns, the Reserve Bank of India decided to keep the repo rate unchanged and maintain a neutral stance at its June monetary policy meeting. This reflects a preference for stability and caution over aggressive policy measures. Although overall inflation remains below the central bank's target range, the bank has acknowledged that upside risks are rising, mainly due to global commodity price fluctuations and supply-side constraints.From a fundamental perspective, the geopolitically driven surge in crude oil prices has significantly altered the inflation outlook. Rising energy prices not only directly impact fuel costs but also trigger chain reactions through transportation, manufacturing, and household consumption, creating broader and more persistent price pressures. Inflation is expected to rise in the coming quarters. Meanwhile, domestic consumption trends in India remain healthy, government capital expenditure continues to support economic activity, corporate balance sheets are the strongest they've been in years, the banking system is well-capitalized, and credit growth remains solid.At the sentiment level, the central bank's decision to pause rate hikes along with its cautious tone suggests that bond yields may remain range-bound in the short term, but as inflation risks accumulate, there is some potential upward bias. The central bank avoided providing explicit forward guidance on interest rates, retaining flexibility to adjust dynamically as the situation evolves. Going forward, key factors to watch include the trajectory of global growth, crude oil price movements, climate-related risks, and the extent to which geopolitical developments spill over into the domestic Indian economy.